Due April 5: Applications for Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR)
NCATS accepting pre-proposals
If you are an academic researcher or small business looking to commercialize your biotech innovation, consider applying for the Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs supported by the National Center for Advancing Translational Sciences (NCATS). The deadline for applications for the Omnibus Solicitation is Apr. 5, 2019, 5:00 p.m. local time.
Small businesses and research organizations involved in commercializing innovative medical technologies are encouraged to apply. NCATS is particularly interested in applications that address research areas relevant to any stage of translation, from target validation through pre-clinical and clinical evaluation, to intervention implementation and dissemination, including:
- Drug Discovery and Development
- Biomedical, Clinical and Health Research Informatics
- Clinical, Dissemination and Implementation Research
SBIR and STTR applicants can apply for Phase I and Phase II funding. SBIR applicants can also now opt to apply for Direct-to-Phase II Funding. This award allows small business concerns to submit Direct-to-Phase II SBIR applications if the small business had performed the Phase I stage-type research through other funding sources. An updated SBIR/STTR Application Guide with additional instructions for the newly reinstated SBIR Direct Phase II application preparation and submission is now available.
Questions? NCATS encourages applicants to email NCATS-SBIRSTTR@mail.nih.gov to discuss potential project ideas and related questions.
There are many benefits to SBIR and STTR funding, including:
- Funding is stable, predictable and not a loan
- Capital is non-dilutive
- Small businesses and research organizations retain intellectual property rights
- SBIR and STTR grants confer eligibility to use other NIH and NCATS support programs and resources
- NIH’s rigorous peer-review provides recognition, validation and visibility to early-stage companies
- Prestige associated with these awards can help attract more funding or other support (e.g., venture capital, strategic partners)